Department of Cancer Biology, Mayo Clinic Cancer Center, Jacksonville, FL 32224, USA.
Department of Cancer Biology, Mayo Clinic Cancer Center, Jacksonville, FL 32224, USA.
Cancer Cell. 2016 Mar 14;29(3):367-378. doi: 10.1016/j.ccell.2016.02.012.
We report that the protein kinase Cι (PKCι) oncogene controls expression of NOTCH3, a key driver of stemness, in KRAS-mediated lung adenocarcinoma (LADC). PKCι activates NOTCH3 expression by phosphorylating the ELF3 transcription factor and driving ELF3 occupancy on the NOTCH3 promoter. PKCι-ELF3-NOTCH3 signaling controls the tumor-initiating cell phenotype by regulating asymmetric cell division, a process necessary for tumor initiation and maintenance. Primary LADC tumors exhibit PKCι-ELF3-NOTCH3 signaling, and combined pharmacologic blockade of PKCι and NOTCH synergistically inhibits tumorigenic behavior in vitro and LADC growth in vivo demonstrating the therapeutic potential of PKCι-ELF3-NOTCH3 signal inhibition to more effectively treat KRAS LADC.
我们报告称,蛋白激酶 Cι(PKCι)癌基因控制 KRAS 介导的肺腺癌(LADC)中NOTCH3 的表达,NOTCH3 是干性的关键驱动因素。PKCι 通过磷酸化 ELF3 转录因子并驱动 ELF3 占据 NOTCH3 启动子来激活 NOTCH3 表达。PKCι-ELF3-NOTCH3 信号通过调节不对称细胞分裂来控制肿瘤起始细胞表型,这是肿瘤起始和维持所必需的过程。原发性 LADC 肿瘤表现出 PKCι-ELF3-NOTCH3 信号,并且联合应用 PKCι 和 NOTCH 的药物阻断在体外协同抑制致瘤行为,体内抑制 LADC 生长,证明了抑制 PKCι-ELF3-NOTCH3 信号以更有效地治疗 KRAS LADC 的治疗潜力。